BeautyHealth Sees FY26 Adjusted EBITDA of $35M-$45M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy SKIN?
Sees FY26 adjusted EBITDA $35M-$45M. The company said, "BeautyHealth enters 2026 with a strong foundation - a globally recognized brand, one of the largest installed bases in aesthetics, and a strong recurring consumables model. Our focus now is to unlock the full economic potential of our platform by strengthening commercial execution, expanding utilization, improving provider economics, and investing in clinically meaningful innovation."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SKIN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SKIN
Wall Street analysts forecast SKIN stock price to rise
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 0.927
Low
1.60
Averages
1.63
High
1.65
Current: 0.927
Low
1.60
Averages
1.63
High
1.65
About SKIN
The Beauty Health Company is a medical technology meets beauty company that delivers skin-health experiences. The Company and its subsidiaries design, develop, manufacture, market, and sell esthetic technologies and products. It specializes in skin health for all ages, genders, skin tones, and skin types. Its brands include Hydrafacial, SkinStylus, and Keravive. Hydrafacial created the category of hydradermabrasion with its patented delivery system that cleanses, extracts, and hydrates the skin with proprietary solutions and serums. SkinStylus specializes in nanoneedling and microneedling, where its products are designed to provide either a non-invasive (nanoneedling) or minimally invasive (microneedling) skin treatment to individuals. Keravive specializes in scalp health with its products that are designed to support the hair’s natural growth by cleansing, exfoliating, and hydrating the scalp and hair follicles.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Beauty Health Company Q4 2025 Earnings Call Insights
- Revenue Performance: In Q4 2025, total revenue reached $82.4 million, reflecting a 1.3% year-over-year decline, yet showing significant improvement from the previous quarter's double-digit drop, with consumables revenue rising to $57.7 million, indicating resilience and potential in the market.
- Margin Improvement: The CFO reported an increase in adjusted gross margins from 62% to over 68%, while GAAP gross margins rose from 54.5% to 65.3%, demonstrating substantial progress in cost control and profitability.
- Future Outlook: For 2026, the company anticipates revenue between $285 million and $305 million, with expectations that the first half may be slightly below last year, but a recovery is expected in the second half, reflecting management's confidence in future growth.
- Strategic Focus: The CEO emphasized that 2026 will be an execution year, concentrating on sales force excellence, marketing discipline, and innovation, particularly the early development of the next-generation Hydrafacial system targeted for launch in 2028, aimed at enhancing market competitiveness.
See More
Beauty Health Q4 Earnings Report Analysis
- Earnings Performance: Beauty Health reported a Q4 GAAP EPS of -$0.06, missing expectations by $0.01, indicating challenges in profitability that could affect investor confidence.
- Revenue Figures: The company generated $82.4 million in revenue, a 1.3% year-over-year decline, although it beat market expectations by $4.28 million; however, the ongoing revenue decline may pressure future growth prospects.
- Market Reaction: The earnings miss may lead investors to question the company's future profitability, resulting in increased stock price volatility and impacting overall market confidence in Beauty Health.
- Strategic Implications: Despite exceeding revenue expectations, the persistent losses and declining revenue may prompt the company to reassess its market strategy to address challenges posed by intensified competition and changing consumer demands.
See More
Beauty Health (SKIN) Q4 Earnings Preview
- Earnings Announcement Date: Beauty Health (SKIN) is set to announce its Q4 earnings on March 12th after market close, with investors keenly awaiting its performance and future outlook.
- Earnings Expectations: The consensus EPS estimate stands at -$0.05, reflecting a 37.5% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Expectations: The consensus revenue estimate is $78.12 million, representing a 6.4% year-over-year decline, highlighting challenges and sales pressures faced by the company in a competitive market.
- Historical Performance Review: Over the past year, SKIN has exceeded EPS estimates 25% of the time and revenue estimates 75% of the time, suggesting a degree of capability to outperform expectations.
See More
Beauty Health Company to Report Q4 and Full Year 2025 Results
- Earnings Report Schedule: The Beauty Health Company (NASDAQ:SKIN) will release its fourth quarter and full year 2025 financial results after market close on March 12, 2026, providing investors with critical performance data and future outlook.
- Investor Conference Call: Following the earnings release, the company will host an investor conference call at 4:30 p.m. Eastern Time, aimed at discussing financial results and strategic direction in depth, enhancing transparency and communication.
- Webcast Access: Investors can access the live webcast of the conference call through the company's investor relations website, ensuring all stakeholders can obtain real-time information and improving the convenience of information disclosure.
- Compliance Disclosure: The Beauty Health Company discloses material information to the public through various channels, including SEC filings, press releases, and public conference calls, ensuring compliance with regulatory requirements and maintaining investor trust.
See More
Beauty Health Company Under Investigation for Restructuring Charges, Sales Guidance Revised to $385-$400 Million
- Declining Financial Performance: Beauty Health Company reported lower-than-expected U.S. revenue in its Q3 2023 results, incurring $63.1 million in restructuring charges related to early-generation Syndeo device upgrades, indicating significant financial strain.
- Sales Guidance Revision: The company has revised its fiscal year 2023 net sales guidance to a range of $385 to $400 million, with adjusted EBITDA margin guidance lowered to 5% to 6%, reflecting uncertainty in future profitability.
- Executive Changes: CEO Stanleick will depart from his roles as President and CEO and relinquish his board seat, which may impact the company's strategic direction and market confidence.
- Legal Litigation Risks: The company and certain executives are facing a securities class action lawsuit for failing to disclose material information, with KSF investigating potential breaches of fiduciary duties, which could negatively affect the company's reputation and stock price.
See More
Skinesa® Achieves No. 2 on 2025 Gator100 with 665% CAGR
- Rapid Growth: Skinesa® achieved a remarkable 665% CAGR over the past three years, earning the No. 2 spot on the University of Florida's Gator100 list, which underscores its leadership and commitment to scientific excellence in the probiotic skincare industry.
- Market Expansion: This year, the company launched chewable skin probiotics for kids, which not only diversifies its product line but also enhances its competitive edge and market share in the skincare sector.
- Strengthened Partnerships: Skinesa® is reinforcing its collaborations with doctors and healthcare professionals to solidify its research position in the skincare industry, which will help enhance brand credibility and customer trust.
- Leadership Remarks: CEO Ryan Walters expressed that earning the No. 2 spot on the Gator100 is a tremendous honor, reflecting the company's values in innovation, leadership, and problem-solving, further motivating the team to pursue purposeful and integrity-driven growth.
See More
Beauty Health Company Q4 2025 Earnings Call Insights
- Revenue Performance: In Q4 2025, total revenue reached $82.4 million, reflecting a 1.3% year-over-year decline, yet showing significant improvement from the previous quarter's double-digit drop, with consumables revenue rising to $57.7 million, indicating resilience and potential in the market.
- Margin Improvement: The CFO reported an increase in adjusted gross margins from 62% to over 68%, while GAAP gross margins rose from 54.5% to 65.3%, demonstrating substantial progress in cost control and profitability.
- Future Outlook: For 2026, the company anticipates revenue between $285 million and $305 million, with expectations that the first half may be slightly below last year, but a recovery is expected in the second half, reflecting management's confidence in future growth.
- Strategic Focus: The CEO emphasized that 2026 will be an execution year, concentrating on sales force excellence, marketing discipline, and innovation, particularly the early development of the next-generation Hydrafacial system targeted for launch in 2028, aimed at enhancing market competitiveness.
See More
Beauty Health Q4 Earnings Report Analysis
- Earnings Performance: Beauty Health reported a Q4 GAAP EPS of -$0.06, missing expectations by $0.01, indicating challenges in profitability that could affect investor confidence.
- Revenue Figures: The company generated $82.4 million in revenue, a 1.3% year-over-year decline, although it beat market expectations by $4.28 million; however, the ongoing revenue decline may pressure future growth prospects.
- Market Reaction: The earnings miss may lead investors to question the company's future profitability, resulting in increased stock price volatility and impacting overall market confidence in Beauty Health.
- Strategic Implications: Despite exceeding revenue expectations, the persistent losses and declining revenue may prompt the company to reassess its market strategy to address challenges posed by intensified competition and changing consumer demands.
See More
Beauty Health (SKIN) Q4 Earnings Preview
- Earnings Announcement Date: Beauty Health (SKIN) is set to announce its Q4 earnings on March 12th after market close, with investors keenly awaiting its performance and future outlook.
- Earnings Expectations: The consensus EPS estimate stands at -$0.05, reflecting a 37.5% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Expectations: The consensus revenue estimate is $78.12 million, representing a 6.4% year-over-year decline, highlighting challenges and sales pressures faced by the company in a competitive market.
- Historical Performance Review: Over the past year, SKIN has exceeded EPS estimates 25% of the time and revenue estimates 75% of the time, suggesting a degree of capability to outperform expectations.
See More
Beauty Health Company to Report Q4 and Full Year 2025 Results
- Earnings Report Schedule: The Beauty Health Company (NASDAQ:SKIN) will release its fourth quarter and full year 2025 financial results after market close on March 12, 2026, providing investors with critical performance data and future outlook.
- Investor Conference Call: Following the earnings release, the company will host an investor conference call at 4:30 p.m. Eastern Time, aimed at discussing financial results and strategic direction in depth, enhancing transparency and communication.
- Webcast Access: Investors can access the live webcast of the conference call through the company's investor relations website, ensuring all stakeholders can obtain real-time information and improving the convenience of information disclosure.
- Compliance Disclosure: The Beauty Health Company discloses material information to the public through various channels, including SEC filings, press releases, and public conference calls, ensuring compliance with regulatory requirements and maintaining investor trust.
See More
Beauty Health Company Under Investigation for Restructuring Charges, Sales Guidance Revised to $385-$400 Million
- Declining Financial Performance: Beauty Health Company reported lower-than-expected U.S. revenue in its Q3 2023 results, incurring $63.1 million in restructuring charges related to early-generation Syndeo device upgrades, indicating significant financial strain.
- Sales Guidance Revision: The company has revised its fiscal year 2023 net sales guidance to a range of $385 to $400 million, with adjusted EBITDA margin guidance lowered to 5% to 6%, reflecting uncertainty in future profitability.
- Executive Changes: CEO Stanleick will depart from his roles as President and CEO and relinquish his board seat, which may impact the company's strategic direction and market confidence.
- Legal Litigation Risks: The company and certain executives are facing a securities class action lawsuit for failing to disclose material information, with KSF investigating potential breaches of fiduciary duties, which could negatively affect the company's reputation and stock price.
See More
Skinesa® Achieves No. 2 on 2025 Gator100 with 665% CAGR
- Rapid Growth: Skinesa® achieved a remarkable 665% CAGR over the past three years, earning the No. 2 spot on the University of Florida's Gator100 list, which underscores its leadership and commitment to scientific excellence in the probiotic skincare industry.
- Market Expansion: This year, the company launched chewable skin probiotics for kids, which not only diversifies its product line but also enhances its competitive edge and market share in the skincare sector.
- Strengthened Partnerships: Skinesa® is reinforcing its collaborations with doctors and healthcare professionals to solidify its research position in the skincare industry, which will help enhance brand credibility and customer trust.
- Leadership Remarks: CEO Ryan Walters expressed that earning the No. 2 spot on the Gator100 is a tremendous honor, reflecting the company's values in innovation, leadership, and problem-solving, further motivating the team to pursue purposeful and integrity-driven growth.
See More
